Literature DB >> 24787762

Impact of estimated GFR reporting on late referral rates and practice patterns for end-stage kidney disease patients: a multilevel logistic regression analysis using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA).

Celine Foote1, Philip A Clayton2, David W Johnson3, Meg Jardine4, Paul Snelling5, Alan Cass6.   

Abstract

BACKGROUND: Late referral for renal replacement therapy (RRT) leads to worse outcomes. In 2005, estimated glomerular filtration rate (eGFR) reporting began in Australasia, with an aim of substantially increasing earlier disease detection. STUDY
DESIGN: Observational cohort study using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) data. SETTING & PARTICIPANTS: All patients commencing RRT in Australasia between January 1, 1999, and December 31, 2010. We excluded the period between December 31, 2004, and January 1, 2007, to allow for practice change. FACTOR: Introduction of eGFR reporting. OUTCOMES: Primary outcome was late referral defined as commencing RRT within 3 months of nephrology referral. Secondary outcomes included initial RRT modality and prepared access at hemodialysis therapy initiation. MEASUREMENTS: Late referral rates per era were determined and multilevel logistic regression was used to identify late referral predictors.
RESULTS: We included 25,009 patients. Overall, 3,433 (25.3%) patients were referred late in the pre-eGFR era compared with 2,464 (21.6%) in the post-eGFR era, for an absolute reduction of 3.7% (95% CI, 2.7%-4.8%; P<0.001). After adjustments for age, body mass index, race, comorbid conditions, and primary kidney disease, adjusted late referral rates were 25.8% (95% CI, 23.3%-28.3%) and 21.8% (95% CI, 19.2%-24.4%) in the pre- and post-eGFR eras, respectively, for a difference of 4.0% (95% CI, 1.2%-6.8%; P=0.005). Late referral risk was attenuated significantly post-eGFR reporting (OR, 1.30; 95% CI, 1.12-1.51) compared to pre-eGFR reporting (OR, 2.15; 95% CI, 1.88-2.46) for indigenous patients. Late referral rates decreased for older patients but increased slightly for younger patients (P=0.001 for interaction between age and era). There was no impact on initial RRT modality or prepared access rates at hemodialysis therapy initiation between eras. LIMITATIONS: Residual confounding could not be excluded.
CONCLUSIONS: eGFR reporting was associated with small reductions in late referral, but more than 1 in 5 patients are still referred late. Other initiatives to increase timely referral warrant investigation.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Estimated glomerular filtration rate (eGFR); automatic; late referral; nephrology referral; practice patterns; registry study; renal replacement therapy (RRT)

Mesh:

Year:  2014        PMID: 24787762     DOI: 10.1053/j.ajkd.2014.02.023

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

1.  Early Requirement for RRT in Children at Presentation in the United Kingdom: Association with Transplantation and Survival.

Authors:  Rishi Pruthi; Anna Casula; Carol Inward; Paul Roderick; Manish D Sinha
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-15       Impact factor: 8.237

2.  Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study.

Authors:  Oskar Swartling; Yuanhang Yang; Catherine M Clase; Edouard L Fu; Manfred Hecking; Sebastian Hödlmoser; Ylva Trolle-Lagerros; Marie Evans; Juan J Carrero
Journal:  J Am Soc Nephrol       Date:  2022-07-29       Impact factor: 14.978

3.  Unplanned hemodialysis initiation and low geriatric nutritional risk index scores are associated with end-stage renal disease outcomes.

Authors:  Ryoichi Maenosono; Tatsuo Fukushima; Daisuke Kobayashi; Tomohisa Matsunaga; Yusuke Yano; Shunri Taniguchi; Yuya Fujiwara; Kazumasa Komura; Hirofumi Uehara; Maki Kagitani; Hajime Hirano; Teruo Inamoto; Hayahito Nomi; Haruhito Azuma
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

Review 4.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.

Authors:  Merlin C Thomas; Mark E Cooper; Paul Zimmet
Journal:  Nat Rev Nephrol       Date:  2015-11-10       Impact factor: 28.314

5.  Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease.

Authors:  Htay Htay; David W Johnson; Jonathan C Craig; Armando Teixeira-Pinto; Carmel M Hawley; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2021-01-27

6.  Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease.

Authors:  Htay Htay; David W Johnson; Jonathan C Craig; Armando Teixeira-Pinto; Carmel M Hawley; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2020-12-15

7.  Outcomes of predialysis nephrology care in elderly patients beginning to undergo dialysis.

Authors:  Seon Ha Baek; Shin young Ahn; Sung Woo Lee; Youn Su Park; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Suhnggwon Kim; Ho Jun Chin
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

8.  Māori patients' experiences and perspectives of chronic kidney disease: a New Zealand qualitative interview study.

Authors:  Rachael C Walker; Shayne Walker; Rachael L Morton; Allison Tong; Kirsten Howard; Suetonia C Palmer
Journal:  BMJ Open       Date:  2017-01-19       Impact factor: 2.692

9.  Trends in the Management of Patients With Kidney Failure in Alberta, Canada (2004-2013).

Authors:  Christy C Chong; Helen Tam-Tham; Brenda R Hemmelgarn; Robert G Weaver; Nairne Scott-Douglas; Marcello Tonelli; Robert R Quinn; Liam Manns; Braden J Manns
Journal:  Can J Kidney Health Dis       Date:  2017-03-22

Review 10.  Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria.

Authors:  P Iyngkaran; M Thomas
Journal:  Clin Med Insights Cardiol       Date:  2015-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.